Drug
Adagrasib clinical trials
Also written MRTX849, Krazati, BMS-986503 and KRAS G12C Inhibitor MRTX849.
- studies test it
- 28
- open now
- 9
- in phase 3
- 4
- first study started
- 2019
Keep track of what changes. Save the adagrasib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
28 studies that test it; most in 2023 (8)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 8 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 15
- Phase 2
- 10
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 13
Mirati Therapeutics Inc. (13) · M.D. Anderson Cancer Center (7) · Alliance for Clinical Trials in Oncology (1) · ETOP IBCSG Partners Foundation (1) · Roswell Park Cancer Institute (1) · City of Hope Medical Center (1) · Ryan Gentzler, MD (1) · Incyte Corporation (1)
Often tested with
Tested in the same studies.
Cetuximab (4) · Irinotecan (2) · Bevacizumab (2) · Durvalumab (2) · Abemaciclib (1) · Entrectinib (1) · Batoprotafib (1) · Palbociclib (1)
Studies
Open first, then newest update. How each study uses adagrasib is read from its arms, and is right about nine times in ten.
Testing it · 28
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialRecruitingPhase 2City of Hope Medical CenterNCT07288034Written as Adagrasib
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Adagrasib
- Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7RecruitingPhase 2/3Mirati Therapeutics Inc.NCT04613596Written as Adagrasib
- A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)RecruitingPhase 3Mirati Therapeutics Inc.NCT06875310Written as Adagrasib
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib StudiesRecruitingPhase 2Mirati Therapeutics Inc.NCT07415031Written as Adagrasib
- CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung CancerNot yet recruitingPhase 2Roswell Park Cancer InstituteNCT07543172Written as Adagrasib
- Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A TrialRecruitingPhase 1M.D. Anderson Cancer CenterNCT07382726Written as Adagrasib
- A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C MutationsRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06412198Written as Adagrasib
- Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain MetastasesRecruitingPhase 2Ryan Gentzler, MDNCT06248606Written as Adagrasib
- Genetic Testing in Guiding Treatment for Patients With Brain MetastasesActive, not recruitingPhase 2Alliance for Clinical Trials in OncologyNCT03994796Written as Adagrasib
- Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)Active, not recruitingPhase 3Mirati Therapeutics Inc.NCT04793958Written as MRTX849
- A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese DescentCompletedPhase 1Mirati Therapeutics Inc.NCT07723118Written as Adagrasib
- A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C MutationTerminatedPhase 1Incyte CorporationNCT06039384Written as adagrasib
- Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance StatusActive, not recruitingPhase 2ETOP IBCSG Partners FoundationNCT05673187Written as Adagrasib
- Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT05722327Written as MRTX849
- Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Active, not recruitingPhase 2Mirati Therapeutics Inc.NCT05853575Written as Adagrasib
- Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationActive, not recruitingPhase 3Mirati Therapeutics Inc.NCT04685135Written as MRTX849
- Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung CancersTerminatedPhase 1M.D. Anderson Cancer CenterNCT06130254Written as Adagrasib
- Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without NivolumabWithdrawnPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05472623Written as Adagrasib
- Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer PatientsWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05634525Written as MRTX849
See all 28 studies that test adagrasib →
Given in every arm · 6 — adagrasib is usual care beside what is tested
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsRecruitingPhase 1Kura Oncology, Inc.NCT06026410Written as Adagrasib
- A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsRecruitingPhase 1Bristol-Myers SquibbNCT06764771Written as Adagrasib
- Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingPhase 1/2Mirati Therapeutics Inc.NCT03785249Written as MRTX849
- A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK PathwayTerminatedPhase 1Mirati Therapeutics Inc.NCT05578092Written as MRTX849
- A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid TumorsTerminatedPhase 1/2Bristol-Myers SquibbNCT06024174Written as Adagrasib
- Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced MalignanciesTerminatedPhase 1/2SanofiNCT04418661Written as Adagrasib
As the comparator · 1 — what is tested is compared with adagrasib
Codes
What other systems call adagrasib · ClinicalTrials.gg INT001658
- MeSH (NLM) C000718190adagrasibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8EOO6HQF8YADAGRASIBConfirmed FDA, NLM, Wikidata
- Wikidata Q105816120adagrasibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C157493AdagrasibOne source FDA
- DrugBank DB15568One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718190 | adagrasib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8EOO6HQF8Y | ADAGRASIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q105816120 | adagrasib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C157493 | Adagrasib | One source FDA |
| DrugBank | DB15568 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.